Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Theralase Technologies Inc. V.TLT

Alternate Symbol(s):  TLTFF

Healthcare Medical Devices
Theralase Technologies Inc. is a Canada-based clinical stage pharmaceutical company. The Company is engaged in the research and development of light, radiation, sound and/or drug-activated small molecule compounds, their associated drug formulations and the light systems that activate them, with a primary objective of efficacy and a secondary objective of safety in the destruction of various... see more

Recent & Breaking News (TSXV:TLT)

Today’s market summary: cannabis stocks lift sentiment as blockade enters second week

Trevor Abes  February 9, 2022

Theralase Technologies Moves a Step Closer to Canadian COVID Vaccine

Trevor Abes  February 7, 2022

Theralase® Demonstrates Proof-of-Concept for Canadian-Made COVID-19 Vaccine

GlobeNewswire February 7, 2022

Theralase Expands Intellectual Property Portfolio

GlobeNewswire December 9, 2021

Theralase Releases 3Q21 Financial Statements and Newsletter

GlobeNewswire November 29, 2021

Theralase Announces Leadership Reorganization

GlobeNewswire November 15, 2021

Theralase Releases Q221 Unaudited Financial Statements and Quarterly Newsletter

GlobeNewswire August 30, 2021

Theralase Announces Leadership Transition

GlobeNewswire August 19, 2021

Theralase Releases Q12021 Interim Financial Statements

GlobeNewswire May 28, 2021

Theralase Release FY2020 Audited Financial Statements

ACCESS Newswire April 28, 2021

Theralase(R) Releases Quarterly Newsletter

ACCESS Newswire April 27, 2021

Theralase Commences Collaborative Research with National Microbiology Laboratory for Development of Coronavirus Vaccine

ACCESS Newswire April 9, 2021

Theralase Launches Anti-Cancer Therapy Research Centre

ACCESS Newswire March 29, 2021

Theralase Launches Sixth Clinical Study Site in the US for Phase II Bladder Cancer Clinical Study

ACCESS Newswire March 25, 2021

Theralase Launches Fifth Clinical Study Site in the US for Phase II Bladder Cancer Clinical Study

ACCESS Newswire February 24, 2021

Theralase(R) Releases Quarterly Newsletter

ACCESS Newswire February 1, 2021

Theralase Launches Fourth Clinical Study Site in the US for Phase II Bladder Cancer Clinical Study

ACCESS Newswire January 27, 2021

Theralase Launches Third Clinical Study Site in the US for Phase II Bladder Cancer Clinical Study

ACCESS Newswire January 25, 2021

Theralase Expands Intellectual Property Portfolio

ACCESS Newswire January 22, 2021

Theralase Launches Second Clinical Study Site in the US for Phase II Bladder Cancer Clinical Study

ACCESS Newswire January 20, 2021